公开(公告)号：WO2019217330A1

公开(公告)日：2019-11-14

申请号：PCT/US2019/030943

申请日：2019-05-06

Applicant: STC. UNM

Inventor： BRUECK, Steven, R.J. ,  FARIA BRICENO, Juan, Jose ,  ZHU, Ruichao

IPC: G01N21/55

Abstract: A system for measuring a periodic array of structures on a sample is provided. The system includes an optical source configured to produce an optical beam; an optical system configured to control the polarization of the optical beam and to focus the optical beam with a first NA 1 on a sample surface and to sweep the angle of incidence across a range of angles with an approximately fixed focal position on a sample surface with a second NA 2 wherein NA 2 > NA 1 ; additional optical components configured to receive the optical beam reflected from the sample surface and to focus the reflected beam onto a detector; and a recording system to record the reflectivity of the sample surface as a function of the angle of incidence.

公开(公告)号：WO2019204634A1

公开(公告)日：2019-10-24

申请号：PCT/US2019/028165

申请日：2019-04-18

Applicant: STC. UNM

Inventor： WANDINGER-NESS, Angela ,  BURANDA, Tione ,  SIMONS, Peter ,  YOUNG, Steve

IPC: C12Q1/04 ,  C12Q1/18 ,  G01N33/483

Abstract: The present invention is directed to the discovery that RapI-GTP, Racl-GTP and Flt3-L can be used as Biomarkers for the early detection of sepsis in patients suspected of a bacterial infection which presents as sepsis or is likely to produce sepsis. In particular, the present invention is directed to methods, assays and kits which may be used to distinguish sepsis (infection) from systematic inflammatory response caused by sterile inflammation in trauma patients. The method may he used to diagnose bacteria infection and/or sepsis and monitor therapy of a patient to allow modification of treatment and/or cessation of treatment.

公开(公告)号：WO2019118420A1

公开(公告)日：2019-06-20

申请号：PCT/US2018/064891

申请日：2018-12-11

Applicant: STC. UNM ,  PARRA, Amalia S. ,  BACA, Justin T. ,  SALAS, Christina ,  DOHME, Evelyn ,  WOOD, Barry ,  MENDOZA, Janette ,  SENTHIL, Arjun

Inventor： PARRA, Amalia S. ,  BACA, Justin T. ,  SALAS, Christina ,  DOHME, Evelyn ,  WOOD, Barry ,  MENDOZA, Janette ,  SENTHIL, Arjun

IPC: G01N33/68 ,  A61B10/00

CPC classification number: G01N33/558 ,  A61B10/0045 ,  A61B2010/0077 ,  A61B2010/008 ,  G01N33/68 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/2871

Abstract: A diagnostic transdermal patch which utilizes a microneedle array and an integrated biochemical assay to detect the presence of biomolecules which are associated with a specific condition or disease, such as mild traumatic brain injury (MTBI).

公开(公告)号：WO2019113431A1

公开(公告)日：2019-06-13

申请号：PCT/US2018/064456

申请日：2018-12-07

Applicant: STC. UNM ,  TIMMINS, Graham ,  LIU, Ke Jian ,  PAN, Rong

Inventor： TIMMINS, Graham ,  LIU, Ke Jian ,  PAN, Rong

IPC: A61K31/395 ,  A61K31/409 ,  A61P9/10

Abstract: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.

公开(公告)号：WO2019023203A8

公开(公告)日：2019-01-31

申请号：PCT/US2018/043442

申请日：2018-07-24

Applicant: STC. UNM ,  LIU, Ke Jian Jim ,  SHEN, Jiangang

Inventor： LIU, Ke Jian Jim ,  SHEN, Jiangang

IPC: A61K31/352 ,  A61P9/00 ,  A61P9/10 ,  A61P25/10

Abstract: A composition includes two or more isoflavone compounds and a pharmaceutically acceptable carrier. In some cases, the isoflavone compounds can include calycosin, formononetin, or daidzein. The composition can be used in methods to treat a subject having at risk of having cerebral ischemia-reperfusion injury and/or hypoxia brain injury.

公开(公告)号：WO2018102439A1

公开(公告)日：2018-06-07

申请号：PCT/US2017/063754

申请日：2017-11-29

Applicant: STC. UNM

Inventor： BUSANA, Tito ,  BRUECK, Steven R.J. ,  FEEZELL, Daniel ,  BEHZADIRAD, Mahmoud

IPC: G01Q70/08 ,  G01Q70/16 ,  G01Q60/06 ,  G01Q60/38 ,  B82Y35/00

CPC classification number: G01Q70/12 ,  G01Q60/06 ,  G01Q60/38 ,  H01L21/02458 ,  H01L21/0254 ,  H01L21/02603 ,  H01L21/0262 ,  H01L21/02639 ,  H01L21/02645

Abstract: Nanowires that may be utilized in microscopy, for example atomic force microscopy (AFM), as part of an AFM probe, as well as for other uses, are disclosed. The nanowires may be formed from a Group III nitride such as an epitaxial layer that may be or include gallium nitride, indium nitride, aluminum nitride, and an alloy of these materials. During use of the AFM probe to measure a topography of a test sample surface, the nanowire can activated and caused to lase and emit a light, thereby illuminating the surface with the light. In an implementation, the light can be collected by the AFM probe itself, for example through an optical fiber to which the nanowire is attached.

公开(公告)号：WO2018023108A1

公开(公告)日：2018-02-01

申请号：PCT/US2017/044619

申请日：2017-07-31

Applicant: STC. UNM

Inventor： DERETIC, Vojo

IPC: A61K31/70 ,  A61K38/21 ,  A61P31/04 ,  A61P35/00

CPC classification number: A61K31/702 ,  A61K31/05 ,  A61K31/137 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/616 ,  A61K31/7016 ,  A61K38/21 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRI.M 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence authophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.

Abstract translation: 本发明涉及通过调节TRIM（含三联基序）蛋白质，尤其是TRIM 8，TRIM：10，TRIM 16，TRIM 19和/或TRI.M 51（ 优选TRIM 16}和半乳糖凝集素，特别是半乳凝素3以影响自体吞噬并治疗许多由自噬介导和/或影响的疾病状态和/或病症，包括炎性疾病状态和/或病症，包括微生物感染 作为分枝杆菌感染，在许多其他疾病中，炎性疾病，溶酶体，储存病症，免疫病症，神经退行性病症和癌症。

公开(公告)号：WO2017165733A1

公开(公告)日：2017-09-28

申请号：PCT/US2017/023969

申请日：2017-03-24

Applicant: STC. UNM ,  EDWARDS, Jeremy, Scott ,  SZAUTER, Paul ,  SINCLAIR, Robert B.

Inventor： EDWARDS, Jeremy, Scott ,  SZAUTER, Paul ,  SINCLAIR, Robert B.

IPC: G01N33/48 ,  C07H21/04 ,  C12Q1/68 ,  C12N15/12 ,  A61D99/00

Abstract: This disclosure describes detecting genetically distinct kinds of inherited myopathies in horses, variously referred to as Polysaccharide Storage Myopathy type 2 (PSSM2), Myofibrillar Myopathy (MFM), or idiopathic myopathy.

Abstract translation: 本公开描述了检测马中遗传性不同种类的遗传性肌病，不同地称为多糖储存肌病2型（PSSM2），肌原纤维肌病（MFM）或特发性肌病。

公开(公告)号：WO2017123492A1

公开(公告)日：2017-07-20

申请号：PCT/US2017/012687

申请日：2017-01-09

Applicant: STC. UNM

Inventor： HALL, Pamela ,  PROSSNITZ, Eric, R. ,  HATHAWAY, Helen, J.

IPC: A61K38/17 ,  C07K14/47 ,  A61K31/138

CPC classification number: A61K35/644 ,  A61K31/4741 ,  A61K38/14 ,  A61K45/06 ,  C07K14/70567 ,  A61K2300/00

Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition -and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bac terial pathogens, including MRSA are also described.

Abstract translation: 本发明涉及作为G蛋白偶联雌激素受体（GPER）的调节剂的化合物用于抑制和/或治疗细菌感染，尤其包括metMctHin抗性 （金黄色葡萄球菌）（MRSA）感染。 还描述了包括MRSA在内的细菌病原体的药物组合物和治疗方法。

公开(公告)号：WO2017023407A2

公开(公告)日：2017-02-09

申请号：PCT/US2016/035289

申请日：2016-06-01

Applicant: STC. UNM ,  JOHNSON, Patrick ,  BRINKER, C., Jeffrey ,  CARNES, Eric ,  TIMMINS, Graham ,  MUTTIL, Pavan

Inventor： JOHNSON, Patrick ,  BRINKER, C., Jeffrey ,  CARNES, Eric ,  TIMMINS, Graham ,  MUTTIL, Pavan

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.

Abstract translation: 本公开描述了涉及生物复合材料的组合物，疫苗和方法。通常，生物复合材料包括细胞和至少部分包封细胞的脂质 - 二氧化硅基质。 在某些情况下，细胞可以存活但不可培养（VBNC）。 在一些情况下，脂质 - 二氧化硅基质包括干燥的溶胶和/或具有有序的纳米结构。